Antiviral therapy in chronic hepatitis C virus infection
Background: Hepatitis C is a disease with significant global impact. According to the World Health Organization there are 71 million people chronically infected with the hepatitis C virus. About 399.000 people die each year, mostly from cirrhosis and hepatocarcinoma. GT 1 and 3 are the most common...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Scientific Medical Association of Moldova
2019-09-01
|
| Series: | The Moldovan Medical Journal |
| Subjects: | |
| Online Access: | http://moldmedjournal.md/wp-content/uploads/2019/09/moldovan-med-j-2019-russu-full-text.pdf |
| Summary: | Background: Hepatitis C is a disease with significant global impact. According to the World Health Organization there are 71 million people chronically
infected with the hepatitis C virus. About 399.000 people die each year, mostly from cirrhosis and hepatocarcinoma. GT 1 and 3 are the most common
causes of infection. Chronic HCV infection is accompanied by extrahepatic manifestations reported in up to 75% of patients, rapid development of hepatic
fibrosis and accelerated time to cirrhosis and increased risk for liver failure, HCC and liver-related mortality. HCV therapy is one of the interventions
necessary to reduce global burden of disease. Because of their high virological efficacy, ease of use, safety and tolerability, IFN-free, ribavirin-free, DAA-based
regimens must be used in HCV-infected patients without cirrhosis or with compensated cirrhosis, including: treatment-naive patients: never been treated
for their HCV infection, treatment-experienced patients: previously treated with PEG-IFNa + RBV. From pangenotypic drugs or drug combinations for
treatment HCV in Europe are recommended: sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir. Genotype-specific
drugs sofosbuvir/ledipasvir, ombitasvir/paritaprevir/ritonavir, or grazoprevir /elbasvir are recommended for (GT 1, 4, 5 and 6).
Conclusions: The new direct-acting antiviral treatment regimens can be given to most patients with chronic hepatitis C virus infection, including those
with liver cirrhosis, they have shown high efficacy, achieving sustained virologic response in over 90% of patients. DAA are well tolerated and have
minimal side effects that do not require treatment discontinuation. |
|---|---|
| ISSN: | 2537-6373 2537-6381 |